Pyxis Oncology, Inc. (PYXS) stock
PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.44+0.03 (+2.13%)
Close on Nov 17, 2026Market cap $120.11MP/E –Yield –
Pyxis Oncology operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Pyxis Oncology's operating cash flow for the twelve months ending Jun 30, 2026 was -$67.91M. For fiscal 2025 it was -$63.50M. The highest annual figure on record is -$10.08M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$63.50M | – |
| FY2024 | Dec 31, 2024 | -$57.67M | – |
| FY2023 | Dec 31, 2023 | -$70.71M | – |
| FY2022 | Dec 31, 2022 | -$89.34M | – |
| FY2021 | Dec 31, 2021 | -$35.33M | – |
| FY2020 | Dec 31, 2020 | -$10.08M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.21M | – |
| Q1 FY2026 | Mar 31, 2026 | -$26.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.43M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.26M | – |
| Q1 FY2025 | Mar 31, 2025 | -$22.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$19.29M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.67M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.01M | – |
| Q1 FY2024 | Mar 31, 2024 | -$20.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.25M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.58M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.03M | – |
| Q1 FY2023 | Mar 31, 2023 | -$26.84M | – |
| Q4 FY2022 | Dec 31, 2022 | -$17.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.71M | -928.5% |
| Q1 FY2022 | Mar 31, 2022 | -$27.68M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.17M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.29M | – |
| Q2 FY2021 | Jun 30, 2021 | $2.86M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.17M | – |
See a number that looks wrong?